NCT03886038View on ClinicalTrials.gov

Subunit Vaccine Against Herpes Zoster in RA Patients Treated With JAK-inhibitors (VACCIMIL-ZOSTER)

PHASE4CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

March 15, 2019

Primary Completion Date

February 15, 2022

Study Completion Date

February 15, 2022

Conditions
Rheumatoid ArthritisHealthy Controls
Interventions
BIOLOGICAL

Shingrix

immunization with 2 doses of a subunit vaccine against herpes-zoster (Shingrix) administrated with at least 2 months apart

Trial Locations (1)

SE-22185

Skåne University hospital, Dept of rheumatology, Lund

All Listed Sponsors
lead

Region Skane

OTHER

NCT03886038 - Subunit Vaccine Against Herpes Zoster in RA Patients Treated With JAK-inhibitors (VACCIMIL-ZOSTER) | Biotech Hunter | Biotech Hunter